Patents Examined by Channing S. Mahatan
  • Patent number: 10538750
    Abstract: This invention relates to reagents and methods for increasing specificity and efficiency of genome editing by CRISPR associated (Cas) protein systems, more particularly by Cas:guide RNA complexes, by blocking off-target nucleic acids from cleavage by Cas:guide RNA complexes.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 21, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Chong Wing Yung, Andrew Kennedy
  • Patent number: 10526609
    Abstract: The present invention provides nucleic acid and protein sequences that enhance the expression of fusion proteins by host cells, and in particular bacterial species, together with methods use thereof. While described hereinafter in terms of expression of fusion proteins by Listeria monocytogenes, the present invention is applicable to expression of fusion proteins generally.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 7, 2020
    Assignee: ADURO BIOTECH, INC.
    Inventors: Peter M. Lauer, William G. Hanson
  • Patent number: 10526573
    Abstract: A microfluidic system for causing perturbations in a cell membrane includes (a) a microfluidic channel defining a lumen and configured such that a cell suspended in a buffer can pass there through, and (b) source or emitter of an energy field. The microfluidic channel may include a cell-deforming constriction. A diameter of the constriction may be a function of the diameter of the cell. Related apparatus, systems, techniques, and articles are also described.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: January 7, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Xiaoyun Ding, Armon R. Sharei, Robert S. Langer, Klavs F. Jensen
  • Patent number: 10526590
    Abstract: The present invention relates to guide RNAs comprising adaptor segments having one or more modifications, and their use in homologous recombination by CRISPR:Cas systems. The modified adaptor segments are resistant to degradation by RNaseH. The present invention also relates to a dual guide RNA strategy in which a first guide RNA directs a Cas enzyme to make a double-strand break at a first target sequence, and a second guide RNA comprises an adaptor segment attached to a donor polynucleotide, and binds a second target sequence that is offset from the first target sequence.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: January 7, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Andrew Kennedy, Gusti Zeiner, Subhadeep Roy, Chong Wing Yung
  • Patent number: 10526589
    Abstract: Methods and constructs for the multiplex expression of highly active CRISPR guide RNAs (gRNAs) from RNA Polymerase II and III promoters, optionally in mammalian cells. The present invention is based, at least in part, on the discovery that Csy4, an endoribonuclease that recognizes a short RNA hairpin sequence, can be used to cleave out multiple functional gRNAs encoded on a single longer RNA transcript (produced from an RNA pol II or III promoter) in which the individual gRNAs are separated by Csy4 cleavage sites.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: January 7, 2020
    Assignee: The General Hospital Corporation
    Inventors: Shengdar Tsai, J. Keith Joung
  • Patent number: 10519417
    Abstract: The invention discloses a high-secretion heat-resistant yeast genetically engineered strain and application thereof, belonging to the field of biotechnology. Mutagenesis and domestication are performed to obtain the yeast genetically engineered strain capable of expressing a lipase gene at a high secretion level at high temperature. The strain is collected by China Center for Type Culture Collection (CCTCC), and the collection number is CCTCC NO: M 2016278. The sequencing analysis shows that the lipase gene and promoter sequence thereof are not mutated, which indicates that the high-secretion expression of the lipase gene by the mutant strain is caused by mutation of other gene sequences in the genome.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 31, 2019
    Assignee: Jiangnan University
    Inventors: Xiaowei Yu, Yan Xu
  • Patent number: 10517877
    Abstract: The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 31, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Aseem Ansari, Graham Erwin, Matthew Grieshop
  • Patent number: 10513699
    Abstract: A method of preparing a conditionally active biologic protein by selecting a wild-type biologic protein, evolving the DNA which encodes the wild-type biologic protein using one or more evolutionary techniques to create mutant DNAs, expressing the mutant DNAs in a eukaryotic cell production host to obtain a mutant protein, subjecting the mutant protein and the wild-type protein to an assay under a normal physiological condition and to an assay under an aberrant condition, selecting a conditionally active mutant protein which exhibits at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type protein, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type protein; and producing the conditionally active biologic protein in the same eukaryotic cell production host used in the expression step.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 24, 2019
    Assignee: BioAtla, LLC
    Inventor: Jay M. Short
  • Patent number: 10501815
    Abstract: Described herein are glucose and insulin sensors. The sensors are composed of host cells with DNA specifically designed to produce fluorescence when the cells come into contact with glucose and/or insulin in the sample. Once the fluorescence has been quantified, it can be correlated with the amount of glucose and/or insulin present in the sample.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: December 10, 2019
    Assignee: International Park of Creativity
    Inventor: Raul Cuero Rengifo
  • Patent number: 10487364
    Abstract: A method for determining a folate substance administration regime is disclosed. The method comprises: quantifying, in a sample drawn from a patient, the expression level of at least one of the genes SLC46A1, SLC19A1, FPGS, ABCC3, MTHFD1 L, GGH, MTHFD1, MTFMT, and ATIC; and establishing whether the expression level is high or low. A high expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate and/or a folate substance upstreams of [6R]-methylenetetrahydrofolate in the metabolic pathway. A low expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate. Also disclosed is a kit for determining such a folate substance administration regime.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 26, 2019
    Assignee: ISOFOL MEDICAL AB
    Inventors: Yvonne Wettergren, Elisabeth Odin
  • Patent number: 10487323
    Abstract: The present invention provides methods for generating a library of synthetic polynucleotides. The present invention also provides methods for generating proteins encoded by the library of synthetic polynucleotides. In addition, provided herein are methods for determining the soluble expression of said proteins. This invention is based, in part, on the discovery of a method for selecting optimal oligonucleotides in combination with performing a phosphorylation reaction, ligation reaction and PCR amplification in a single reaction vessel to produce synthetic polynucleotides in a multiplex manner.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: November 26, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, AGILENT TECHNOLOGIES, INC.
    Inventors: John Christopher Anderson, Bo Curry, Timothy Hsiau
  • Patent number: 10472677
    Abstract: Provided are methods and compositions for inhibiting eukaryotic translation initiation factor eIF4E. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and/or treating cancer.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: November 12, 2019
    Assignee: Translational Therapeutics, Inc.
    Inventors: Gordon A. Jamieson, Jr., Katherine L. B. Borden, Biljana Culjkovic, Alex Kentsis
  • Patent number: 10463263
    Abstract: A multifunctional invasive cardiovascular diagnostic measurement host is disclosed that interfaces a variety of sensor devices, such as guide wire-mounted pressure sensors, flow sensors, temperature sensors, etc, and provides a multi-Mode graphical user interface providing a plurality of displays in accordance with the various types of sensors and measurements rendered by the sensors.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: November 5, 2019
    Assignee: VOLCANO CORPORATION
    Inventors: Howard David Alpert, Paul Michael Hoseit
  • Patent number: 10457948
    Abstract: The present invention resides in a method for the manufacture of a disulphide-requiring biopharmaceutical having an element of at least tertiary structure using wild type E. coli.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 29, 2019
    Assignee: University of Kent
    Inventor: Colin Robinson
  • Patent number: 10443100
    Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with subclinical acute rejection (subAR). These genes sets are useful for diagnosis, prognosis, monitoring of subAR.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 15, 2019
    Assignee: The Scripps Research Institute
    Inventors: Daniel R. Salomon, John Friedewald, Sunil Kurian, Michael M. Abecassis, Steve Head, Phillip Ordoukhanian
  • Patent number: 10443047
    Abstract: Disclosed are methods and compositions for increasing the triacylglycerol content of a cell by up-regulating diacylglycerol acyltransferase and down-regulating triacylglycerol lipase. In some embodiments, a DGA1 protein is expressed and a native TGL3 gene is knocked out, thereby increasing the synthesis of triacylglycerol and decreasing its consumption, respectively.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: October 15, 2019
    Assignee: Novogy, Inc.
    Inventors: Vasiliki Tsakraklides, Elena E. Brevnova
  • Patent number: 10446272
    Abstract: Disclosed herein are kits, compositions, and methods relating to the classification of samples. Methods disclosed herein can be used to identify sample mix-ups. Methods disclosed herein can also be used to diagnose conditions or to support treatment-related decisions.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: October 15, 2019
    Assignee: Veracyte, Inc.
    Inventors: Jonathan I. Wilde, Darya Chudova, Giulia C. Kennedy
  • Patent number: 10405795
    Abstract: A method and system for classifying different types of periorbital dyschromia is disclosed. The method includes providing at least one of a predetermined imaging characteristic and a biological characteristic for each of three different types of periorbital dyschromia, and then measuring the appropriate characteristic on a person exhibiting periorbital dyschromia. The type of periorbital dyschromia exhibited by a person can then be determined by comparing the measured value to the predetermined value and selecting the corresponding type of periorbital dyschromia.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 10, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Karen Marie Osorio, Karen Kay Kalla, Wenzhu Zhao, Bradley Bryan Jarrold
  • Patent number: 10400244
    Abstract: The present invention comprises a novel artificial oligonucleotide sequence which can initiate the transcription of a gene under various conditions at a high level. Further the invention relates to a recombinant DNA fragment comprising the artificial oligonucleotide sequence, an expression plasmid comprising the recombinant DNA fragment and a host cell transformed with the recombinant DNA fragment.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 3, 2019
    Assignee: Clariant International Ltd.
    Inventors: Zdravko Dragovic, Christoph Reisinger, Heiko Dietz
  • Patent number: 10392616
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of a nucleic acid.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: August 27, 2019
    Assignee: Arbor Biotechnologies, Inc.
    Inventors: David R. Cheng, David A. Scott, Winston X. Yan, Shaorong Chong